FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367303944> ?p ?o ?g. }

• W4367303944 abstract "<h3>Objective:</h3> To report findings from a pilot sub-study of the Phase 2b tolebrutinib long-term safety (LTS) study (NCT03889639) that assessed compliance with a wearable ActiGraph device and to describe the Phase 3 validation sub-study design assessing the use of actigraphy in measuring gait changes in participants with progressive multiple sclerosis (PwPMS). <h3>Background:</h3> Gait impairment is a common, clinically relevant issue for MS patients. Traditional disability assessments by Expanded Disability Status Scale [EDSS], Timed 25-Foot Walk are widely used, but more sensitive, objective, and clinically meaningful gait impairment measures are needed. <h3>Design/Methods:</h3> The LTS pilot sub-study assessed compliance with the ActiGraph device (defined as 8/14 compliant days with ≥11h/day of device wear/monitoring period) that monitored gait and activity over 4 one-month monitoring periods. The Phase 3 validation sub-study will recruit ~250 PwPMS from PERSEUS (NCT04458051) and HERCULES (NCT04411641) tolebrutinib trials. Participants will be monitored 14 days/month for ≥12 months. Primary endpoint is correlation of gait measures with standard disability progression assessments. Key gait measures include gait speed, step duration, and step length. Physical activity measures include number of steps and walking episodes. Secondary endpoints are to establish normative values for velocity, stride length, and step duration for subsets of EDSS. <h3>Results:</h3> Compliance in the Actigraphy LTS pilot sub-study was 61%–90% over 4 monitoring periods, with a mean daily wear time ranging from 5.9–14.9h. 79% of participants had a mean daily wear time of >10h. Per literature reports, actigraphy gait measures were correlated with EDSS. Findings from Actigraphy LTS pilot sub-study supported the design of the Phase 3 validation sub-study. <h3>Conclusions:</h3> Actigraphy LTS pilot sub-study showed that participants can use the ActiGraph device with relatively good compliance. This Phase 3 validation sub-study will provide further clinical data on actigraphy as a more sensitive measure to track disability progression in PwPMS. <b>Disclosure:</b> Dr. Abou Zeid has nothing to disclose. Xiaoyu Jiang has received personal compensation for serving as an employee of Sanofi. Dr. Orogun has nothing to disclose. Dr. Sarker has received personal compensation for serving as an employee of Sanofi. Dr. Syed has received personal compensation for serving as an employee of Sanofi US." @default.
• W4367303944 created "2023-04-29" @default.
• W4367303944 creator A5004746670 @default.
• W4367303944 creator A5032630328 @default.
• W4367303944 creator A5033002346 @default.
• W4367303944 creator A5037285485 @default.
• W4367303944 creator A5042483446 @default.
• W4367303944 date "2023-04-25" @default.
• W4367303944 modified "2023-09-26" @default.
• W4367303944 title "Exploring the Utility of ActiGraph in Measuring Gait Impairment and Physical Activity in Patients with MS Using Digital Biomarkers (P3-3.013)" @default.
• W4367303944 doi "https://doi.org/10.1212/wnl.0000000000202191" @default.
• W4367303944 hasPublicationYear "2023" @default.
• W4367303944 type Work @default.
• W4367303944 citedByCount "0" @default.
• W4367303944 crossrefType "proceedings-article" @default.
• W4367303944 hasAuthorship W4367303944A5004746670 @default.
• W4367303944 hasAuthorship W4367303944A5032630328 @default.
• W4367303944 hasAuthorship W4367303944A5033002346 @default.
• W4367303944 hasAuthorship W4367303944A5037285485 @default.
• W4367303944 hasAuthorship W4367303944A5042483446 @default.
• W4367303944 hasConcept C121446783 @default.
• W4367303944 hasConcept C126322002 @default.
• W4367303944 hasConcept C149635348 @default.
• W4367303944 hasConcept C150594956 @default.
• W4367303944 hasConcept C151800584 @default.
• W4367303944 hasConcept C173906292 @default.
• W4367303944 hasConcept C18007350 @default.
• W4367303944 hasConcept C1862650 @default.
• W4367303944 hasConcept C2778996325 @default.
• W4367303944 hasConcept C41008148 @default.
• W4367303944 hasConcept C70770792 @default.
• W4367303944 hasConcept C71924100 @default.
• W4367303944 hasConcept C99508421 @default.
• W4367303944 hasConceptScore W4367303944C121446783 @default.
• W4367303944 hasConceptScore W4367303944C126322002 @default.
• W4367303944 hasConceptScore W4367303944C149635348 @default.
• W4367303944 hasConceptScore W4367303944C150594956 @default.
• W4367303944 hasConceptScore W4367303944C151800584 @default.
• W4367303944 hasConceptScore W4367303944C173906292 @default.
• W4367303944 hasConceptScore W4367303944C18007350 @default.
• W4367303944 hasConceptScore W4367303944C1862650 @default.
• W4367303944 hasConceptScore W4367303944C2778996325 @default.
• W4367303944 hasConceptScore W4367303944C41008148 @default.
• W4367303944 hasConceptScore W4367303944C70770792 @default.
• W4367303944 hasConceptScore W4367303944C71924100 @default.
• W4367303944 hasConceptScore W4367303944C99508421 @default.
• W4367303944 hasLocation W43673039441 @default.
• W4367303944 hasOpenAccess W4367303944 @default.
• W4367303944 hasPrimaryLocation W43673039441 @default.
• W4367303944 hasRelatedWork W2093347606 @default.
• W4367303944 hasRelatedWork W2122766247 @default.
• W4367303944 hasRelatedWork W2136182926 @default.
• W4367303944 hasRelatedWork W2143135552 @default.
• W4367303944 hasRelatedWork W2581454383 @default.
• W4367303944 hasRelatedWork W2591418059 @default.
• W4367303944 hasRelatedWork W271946555 @default.
• W4367303944 hasRelatedWork W2885144544 @default.
• W4367303944 hasRelatedWork W2939231242 @default.
• W4367303944 hasRelatedWork W4246128688 @default.
• W4367303944 isParatext "false" @default.
• W4367303944 isRetracted "false" @default.
• W4367303944 workType "article" @default.